

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

BlackRock Health Sciences Trust
Form N-Q
September 28, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-Q

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811-21702

Name of Fund: BlackRock Health Sciences Trust (BME)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: Anne F. Ackerley, Chief Executive Officer, BlackRock Health Sciences Trust, 55 East 52nd Street, New York, NY 10055.

Registrant's telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 10/31/2010

Date of reporting period: 07/31/2010

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Item 1 Schedule of Investments

Schedule of Investments July 31, 2010 (Unaudited)

BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)

| Common Stocks | Shares | Value |
|---|---------|------------|
| Biotechnology 12.0% | | |
| 3SBio, Inc. - ADR (a) | 35,200 | \$ 529,760 |
| Alexion Pharmaceuticals, Inc. (a) | 10,400 | 565,344 |
| Amgen, Inc. (a) | 53,100 | 2,895,543 |
| Arqule, Inc. (a) | 11,800 | 50,386 |
| BioMarin Pharmaceutical, Inc. (a) | 128,000 | 2,796,800 |
| Celgene Corp. (a) | 134,400 | 7,412,160 |
| Gilead Sciences, Inc. (a) | 161,460 | 5,379,847 |
| Human Genome Sciences, Inc. (a) | 77,600 | 2,012,944 |
| Incyte Corp. Ltd. (a) | 52,500 | 683,550 |
| Ironwood Pharmaceuticals, Inc. (a) | 35,500 | 418,900 |
| Pharmasset, Inc. (a) | 5,200 | 140,452 |
| | | 22,885,686 |
| Chemicals 0.6% | | |
| Sigma-Aldrich Corp. | 19,400 | 1,088,340 |
| Food Products 0.2% | | |
| Synutra International, Inc. (a) | 18,600 | 313,596 |
| Health Care Equipment & Supplies 13.3% | | |
| Alcon, Inc. | 15,300 | 2,372,724 |
| Alere, Inc. (a) | 68,700 | 1,932,531 |
| Becton Dickinson & Co. | 14,000 | 963,200 |
| China Medical Technologies, Inc. - ADR | 28,000 | 287,000 |
| Cooper Cos., Inc. (The) | 36,300 | 1,410,618 |
| Coviden Plc | 17,300 | 645,636 |
| DENTSPLY International, Inc. | 13,900 | 417,278 |
| Gen-Probe, Inc. (a) | 65,100 | 2,927,547 |
| Henry Schein, Inc. (a) | 53,800 | 2,823,962 |
| Hill-Rom Holdings, Inc. | 78,300 | 2,587,032 |
| Hologic, Inc. (a) | 29,000 | 410,060 |
| Medtronic, Inc. | 28,790 | 1,064,366 |
| Nobel Biocare Holding AG | 27,300 | 459,951 |
| Sirona Dental Systems, Inc. (a) | 52,000 | 1,600,560 |
| Sonova Holding AG | 6,200 | 752,359 |
| Trauson Holdings Co. (a) | 128,000 | 59,819 |
| Varian Medical Systems, Inc. (a) | 32,400 | 1,788,480 |
| Zimmer Holdings, Inc. (a) | 57,100 | 3,025,729 |
| | | 25,528,852 |
| Health Care Providers & Services 29.4% | | |
| Aetna, Inc. | 224,100 | 6,241,185 |
| AmerisourceBergen Corp. | 144,200 | 4,321,674 |
| CIGNA Corp. | 92,200 | 2,836,072 |
| Community Health Systems, Inc. (a) | 88,400 | 2,866,812 |
| DaVita, Inc. (a) | 92,800 | 5,319,296 |
| Express Scripts, Inc. (a) | 90,260 | 4,077,947 |
| Fresenius Medical Care AG & Co. KGaA | 109,500 | 6,006,084 |
| McKesson Corp. | 44,700 | 2,808,054 |
| Medco Health Solutions, Inc. (a) | 49,610 | 2,381,280 |
| Mednax, Inc. (a) | 19,400 | 914,710 |

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| | | |
|----------------------------|---------|-----------|
| Patterson Cos., Inc. | 119,800 | 3,196,264 |
| Tenet Healthcare Corp. (a) | 363,300 | 1,671,180 |
| UnitedHealth Group, Inc. | 255,500 | 7,779,975 |
| WellPoint, Inc. (a) | 113,200 | 5,741,504 |

56,162,037

Health Care Technology 7.4%

| | | |
|---|---------|-----------|
| Allscripts-Misys Healthcare Solutions, Inc. (a) | 103,000 | 1,719,070 |
| Biogen Idec, Inc. (a) | 73,500 | 4,107,180 |
| Genzyme Corp. (a) | 30,500 | 2,121,580 |
| Quest Diagnostics, Inc. | 14,600 | 686,054 |
| St. Jude Medical, Inc. (a) | 151,200 | 5,559,624 |

14,193,508

Life Sciences Tools & Services 7.0%

| | | |
|--|--------|-----------|
| Dionex Corp. (a)(b) | 34,900 | 2,634,950 |
| Life Technologies Corp. (a) | 48,300 | 2,076,417 |
| Mettler-Toledo International, Inc. (a) | 30,900 | 3,609,120 |
| Tecan Group AG | 22,100 | 1,389,167 |

Common Stocks

Shares

Value

Life Sciences Tools & Services (concluded)

| | | | |
|------------------------------------|--------|----|-----------|
| Thermo Fisher Scientific, Inc. (a) | 84,000 | \$ | 3,768,240 |
|------------------------------------|--------|----|-----------|

13,477,894

Pharmaceuticals 22.3%

| | | |
|---|---------|------------|
| Abbott Laboratories | 108,100 | 5,305,548 |
| Allergan, Inc. | 30,700 | 1,874,542 |
| Bristol-Myers Squibb Co. (b) | 347,100 | 8,649,732 |
| Eli Lilly & Co. | 30,900 | 1,100,040 |
| GlaxoSmithKline Plc | 94,000 | 1,641,201 |
| Johnson & Johnson | 28,670 | 1,665,440 |
| Merck & Co., Inc. | 77,400 | 2,667,204 |
| Novartis AG, Registered Shares | 75,200 | 3,655,710 |
| Pfizer, Inc. | 810,100 | 12,151,500 |
| Simcere Pharmaceutical Group - ADR (a) | 19,300 | 174,665 |
| Teva Pharmaceutical Industries Ltd. - ADR | 13,050 | 637,493 |
| Watson Pharmaceuticals, Inc. (a) | 79,000 | 3,199,500 |

42,722,575

Total Long-Term Investments

(Cost \$173,209,040) 92.2%

176,372,488

Short-Term Securities

| | | |
|--|------------|------------|
| BlackRock Liquidity Funds, TempFund, Institutional Class, 0.23% (c)(d) | 20,701,114 | 20,701,114 |
|--|------------|------------|

Total Short-Term Securities

(Cost \$20,701,114) 10.8%

20,701,114

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| Options Purchased | Contracts | |
|--|-----------|-------------|
| Exchange-Traded Call Options Purchased 0.0% | | |
| Thoratec Corp., Strike Price USD 44, Expires 8/23/10 | 9 | 90 |
| Thoratec Corp., Strike Price USD 45, Expires 8/23/10 | 91 | 910 |
| Total Options Purchased (Cost \$1,101) 0.0% | | 1,000 |
| Total investments before outstanding options written (Cost \$193,911,255*) 103.0% | | 197,074,602 |

| Options Written | | |
|--|-----|----------|
| Exchange-Traded Call Options Written (0.7%) | | |
| 3SBio, Inc. - ADR, Strike Price USD 15, Expires 9/20/10 | 100 | (9,500) |
| Abbott Laboratories, Strike Price USD 50, Expires 9/20/10 | 325 | (28,600) |
| Abbott Laboratories, Strike Price USD 52.50, Expires 11/22/10 | 100 | (6,850) |
| Aetna, Inc., Strike Price USD 28, Expires 8/23/10 | 220 | (15,180) |
| Aetna, Inc., Strike Price USD 29, Expires 8/23/10 | 370 | (11,100) |
| Aetna, Inc., Strike Price USD 31, Expires 8/23/10 | 150 | (525) |
| Alcon, Inc., Strike Price USD 155, Expires 8/23/10 | 40 | (15,300) |
| Alcon, Inc., Strike Price USD 160, Expires 11/22/10 | 10 | (5,650) |
| Alexion Pharmaceuticals, Inc., Strike Price USD 60, Expires 11/22/10 | 50 | (12,375) |
| Allergan, Inc., Strike Price USD 65, Expires 8/23/10 | 100 | (11,000) |
| Allscripts-Misys Healthcare Solutions, Inc., Strike Price USD 17.50, Expires 9/20/10 | 250 | (11,250) |
| AmerisourceBergen Corp., Strike Price USD 30, Expires 8/23/10 | 685 | (51,375) |

Schedule of Investments (continued)

BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)

| Options Written | Contracts | Value |
|---|-----------|------------|
| Exchange-Traded Call Options Written (continued) | | |
| Amgen, Inc., Strike Price USD 55, Expires 8/23/10 | 75 | \$ (7,350) |
| Amgen, Inc., Strike Price USD 60, Expires 8/23/10 | 100 | (400) |
| Biogen Idec, Inc., Strike Price USD 55, Expires 9/20/10 | 240 | (80,400) |
| Biogen Idec, Inc., Strike Price USD 60, Expires 9/20/10 | 100 | (13,000) |
| BioMarin Pharmaceuticals, Inc., Strike Price USD 20, Expires 8/23/10 | 100 | (21,500) |
| BioMarin Pharmaceuticals, Inc., Strike Price USD 22.50, Expires 8/23/10 | 200 | (13,500) |
| BioMarin Pharmaceuticals, Inc., Strike Price USD 22.50, Expires 9/20/10 | 100 | (9,750) |
| Bristol-Myers Squibb Co., Strike Price USD 25, Expires 8/23/10 | 100 | (4,450) |
| Bristol-Myers Squibb Co., Strike Price USD 26, Expires 8/23/10 | 335 | (3,350) |
| Bristol-Myers Squibb Co., Strike Price USD 26, Expires 9/20/10 | 590 | (21,240) |
| Celgene Corp., Strike Price USD 52.50, Expires 8/23/10 | 150 | (49,125) |
| Celgene Corp., Strike Price USD 57.50, Expires 8/23/10 | 230 | (14,490) |
| Celgene Corp., Strike Price USD 57.50, Expires 9/20/10 | 100 | (13,900) |
| China Medical Technologies, Inc. - ADR, Strike Price USD 11, Expires 8/23/10 | 280 | (7,000) |
| Cigna Corp., Strike Price USD 32, Expires 8/23/10 | 305 | (16,775) |
| Community Health Systems, Inc., Strike Price USD 35, Expires 9/20/10 | 160 | (11,200) |
| Cooper Cos., Inc. (The), Strike Price USD 40, Expires 9/20/10 | 100 | (12,250) |
| Coviden Ltd., Strike Price USD 37.50, Expires 8/23/10 | 93 | (7,905) |
| DaVita, Inc., Strike Price USD 62.50, Expires 9/20/10 | 230 | (10,106) |
| Eli Lilly & Co., Strike Price USD 35, Expires 8/23/10 | 65 | (5,362) |
| Eli Lilly & Co., Strike Price USD 36, Expires 9/20/10 | 25 | (1,325) |
| Express Scripts, Inc., Strike Price USD 45, Expires 8/23/10 | 210 | (30,450) |
| Express Scripts, Inc., Strike Price USD 50, Expires 8/23/10 | 220 | (2,200) |
| Express Scripts, Inc., Strike Price USD 55, Expires 8/23/10 | 100 | (500) |
| Express Scripts, Inc., Strike Price USD 57.50, Expires 11/22/10 | 100 | (2,000) |
| Gen-Probe, Inc., Strike Price USD 50, Expires 8/23/10 | 165 | (1,650) |
| Genzyme Corp., Strike Price USD 52.50, Expires 8/23/10 | 200 | (342,000) |
| | 76 | (111,340) |

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| | | |
|---|-----|----------|
| Genzyme Corp., Strike Price USD 55, Expires 8/23/10 | | |
| Gilead Sciences, Inc., Strike Price USD 35, Expires 9/20/10 | 480 | (43,200) |
| Gilead Sciences, Inc., Strike Price USD 36, Expires 11/22/10 | 100 | (12,500) |
| Henry Schein, Inc., Strike Price USD 55, Expires 9/20/10 | 135 | (10,800) |
| Hill-Rom Holdings, Inc., Strike Price USD 30, Expires 8/23/10 | 100 | (25,000) |
| Hill-Rom Holdings, Inc., Strike Price USD 32.50, Expires 8/31/10 | 160 | (21,105) |
| Hologic, Inc., Strike Price USD 16, Expires 9/20/10 | 170 | (5,100) |

| Options Written | Contracts | Value |
|--|-----------|-------------|
| Exchange-Traded Call Options Written (continued) | | |
| Human Genom Science, Inc., Strike Price USD 25, Expires 8/23/10 | 235 | \$ (39,245) |
| Incyte Corp. Ltd., Strike Price USD 15, Expires 8/23/10 | 300 | (2,250) |
| Incyte Corp. Ltd., Strike Price USD 15, Expires 9/20/10 | 155 | (5,425) |
| Inverness Medical Innovations, Inc., Strike Price USD 35, Expires 8/23/10 | 150 | (1,500) |
| Ironwood Pharmaceuticals, Inc., Strike Price USD 15, Expires 8/23/10 | 10 | (400) |
| Ironwood Pharmaceuticals, Inc., Strike Price USD 17.50, Expires 11/22/10 | 100 | (10,500) |
| Johnson & Johnson, Strike Price USD 60, Expires 8/23/10 | 259 | (4,662) |
| Life Technologies Corp., Strike Price USD 53.50, Expires 8/23/10 | 120 | (2,240) |
| McKesson, Corp., Strike Price USD 70, Expires 8/23/10 | 150 | (750) |
| McKesson, Corp., Strike Price USD 72.50, Expires 8/23/10 | 185 | (925) |
| Medco Health Solutions, Inc., Strike Price USD 56, Expires 8/23/10 | 60 | (158) |
| Medco Health Solutions, Inc., Strike Price USD 60, Expires 9/20/10 | 100 | (1,000) |
| Mednax, Inc., Strike Price USD 60, Expires 8/23/10 | 60 | (300) |
| Medtronic, Inc., Strike Price USD 40, Expires 8/23/10 | 150 | (1,200) |
| Merck & Co., Inc., Strike Price USD 36, Expires 8/23/10 | 200 | (3,600) |
| Merck & Co., Inc., Strike Price USD 37, Expires 8/23/10 | 100 | (650) |
| Patterson Cos., Inc., Strike Price USD 30, Expires 8/23/10 | 150 | (750) |
| Pfizer, Inc., Strike Price USD 15, Expires 8/23/10 | 458 | (16,488) |
| Pfizer, Inc., Strike Price USD 16, Expires 8/23/10 | 542 | (5,962) |
| Quest Diagnostics, Inc., Strike Price USD 55, Expires 8/23/10 | 50 | (375) |
| Sigma-Aldrich Corp., Strike Price USD 60, Expires 9/20/10 | 55 | (1,925) |
| Sirona Dental Systems, Inc., Strike Price USD 35, Expires 8/23/10 | 50 | (875) |
| Sirona Dental Systems, Inc., Strike Price USD 40, Expires 8/23/10 | 120 | (1,200) |
| St. Jude Medical, Inc., Strike Price USD 40, Expires 11/02/10 | 100 | (7,366) |
| St. Jude Medical, Inc., Strike Price USD 40, Expires 8/23/10 | 350 | (3,500) |
| | 500 | (17,500) |

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| | | |
|--|-----|----------|
| Tenet Healthcare Corp., Strike Price USD 5, Expires 11/22/10 | | |
| Teva Pharmaceutical Ltd. - ADR, Strike Price USD 55, Expires 8/23/10 | 50 | (525) |
| Thermo Fisher Scientific, Inc., Strike Price USD 48, Expires 8/23/10 | 390 | (11,370) |
| Thermo Fisher Scientific, Inc., Strike Price USD 52.50, Expires 9/20/10 | 240 | (5,433) |
| Thermo Fisher Scientific, Inc., Strike Price USD 55, Expires 8/23/10 | 40 | (400) |
| Thermo Fisher Scientific, Inc., Strike Price USD 55, Expires 9/20/10 | 90 | (900) |
| Thoratec Corp., Strike Price USD 50, Expires 8/23/10 | 100 | (500) |
| UnitedHealth Group, Inc., Strike Price USD 31, Expires 8/23/10 | 190 | (10,640) |
| UnitedHealth Group, Inc., Strike Price USD 32, Expires 9/20/10 | 120 | (6,900) |

JULY 31, 2010

2

Schedule of Investments (continued)

BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)

| Options Written | Contracts | Value |
|--|-----------|--------------------|
| Exchange-Traded Call Options Written (concluded) | | |
| UnitedHealth Group, Inc., Strike Price USD 33, Expires 8/23/10 | 100 | \$ (900) |
| Varian Medical Systems, Inc., Strike Price USD 55, Expires 8/23/10 | 100 | (15,000) |
| Watson Pharmaceuticals, Inc., Strike Price USD 45, Expires 8/23/10 | 250 | (2,500) |
| WellPoint, Inc., Strike Price USD 55, Expires 8/23/10 | 215 | (3,010) |
| WellPoint, Inc., Strike Price USD 55, Expires 9/20/10 | 150 | (9,825) |
| Zimmer Holdings, Inc., Strike Price USD 55, Expires 8/23/10 | 155 | (6,588) |
| Zimmer Holdings, Inc., Strike Price USD 60.50, Expires 8/06/10 | 150 | (1,180) |
| Total Exchange-Traded Call Options Written | | (1,317,345) |
| Exchange-Traded Put Options Written (0.0)% | | |
| Abbott Laboratories, Strike Price USD 48, Expires 8/23/10 | 200 | (8,600) |
| Aetna, Inc., Strike Price USD 27, Expires 8/23/10 | 75 | (3,188) |
| BioMarin Pharmaceuticals, Inc., Strike Price USD 20, Expires 8/23/10 | 255 | (6,375) |
| Bristol-Myers Squibb Co., Strike Price USD 24, Expires 8/23/10 | 100 | (1,950) |
| Gilead Sciences, Inc., Strike Price USD 31, Expires 8/23/10 | 150 | (4,125) |
| Gilead Sciences, Inc., Strike Price USD 32, Expires 8/23/10 | 150 | (6,975) |
| UnitedHealth Group, Inc., Strike Price USD 29, Expires 9/20/10 | 120 | (25,800) |
| WellPoint, Inc., Strike Price USD 47.50, Expires 8/23/10 | 35 | (1,382) |
| Total Exchange-Traded Put Options Written | | (58,395) |
| Over-the-Counter Call Options Written (0.1)% | | |
| Bristol-Myers Squibb Co., Strike Price USD 26, Expires 11/02/10, Broker Morgan Stanley & Co., Inc. | 10,000 | (6,710) |
| Bristol-Myers Squibb Co., Strike Price USD 26, Expires 9/24/10, Broker Goldman Sachs & Co. | 10,000 | (3,181) |
| Covidien Plc, Strike Price USD 40.18, Expires 9/08/10, Broker JPMorgan Chase Securities | 8,000 | (2,136) |
| Dionex Corp., Strike Price USD 80.07, Expires 8/13/10, Broker UBS Securities LLC | 12,000 | (6,722) |
| Eli Lilly & Co., Strike Price USD 35.04, Expires 8/04/10, Broker Morgan Stanley & Co., Inc. | 2,500 | (1,503) |

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| | | |
|---|--------|----------|
| Fresenius Medical Care AG & Co. KGaA, Strike Price EUR 42, Expires 9/17/10, Broker Morgan Stanley & Co., Inc. | 73 | (11,794) |
| Fresenius Medical Care AG & Co. KGaA, Strike Price EUR 43.69, Expires 9/28/10, Broker Citigroup Global Markets | 15,500 | (11,661) |
| Fresenius Medical Care AG & Co. KGaA, Strike Price EUR 45, Expires 8/20/10, Broker Morgan Stanley & Co., Inc. | 150 | (873) |
| GlaxoSmithKline Plc, Strike Price GBP 11.98, Expires 9/14/10, Broker Citigroup Global Markets | 25,500 | (1,837) |
| Mettler-Toledo International, Inc., Strike Price USD 117.21, Expires 8/27/10, Broker Morgan Stanley & Co., Inc. | 5,000 | (9,861) |
| Mettler-Toledo International, Inc., Strike Price USD 119.54, Expires 8/27/10, Broker Morgan Stanley & Co., Inc. | 5,000 | (5,435) |

| Options Written | Contracts | Value |
|--|-----------|-----------------------|
| Over-the-Counter Call Options Written (concluded) | | |
| Nobel Biocare Holding AG, Strike Price CHF 23, Expires 8/20/10, Broker Deutsche Bank Securities | 100 | \$ (1,012) |
| Novartis AG, Registered Shares, Strike Price CHF 53.83, Expires 8/10/10, Broker Deutsche Bank Securities | 11,000 | (158) |
| Pfizer, Inc., Strike Price USD 15.29, Expires 11/02/10, Broker Credit Suisse First Boston | 156,000 | (102,618) |
| Pfizer, Inc., Strike Price USD 16, Expires 11/02/10, Broker Morgan Stanley & Co., Inc. | 40,000 | (17,480) |
| St. Jude Medical, Inc., Strike Price USD 39, Expires 11/02/10, Broker Morgan Stanley & Co., Inc. | 10,000 | (10,800) |
| Tecan Group AG, Registered Shares, Strike Price CHF 70.40, Expires 9/01/10, Broker Deutsche Bank Securities | 7,800 | (7,921) |
| Tenet Healthcare Corp., Strike Price USD 5, Expires 11/02/10, Broker Morgan Stanley & Co., Inc. | 70,000 | (20,930) |
| Teva Pharmaceutical Ltd. - ADR, Strike Price USD 56.42, Expires 8/31/10, Broker UBS Securities LLC | 8,000 | (1,653) |
| UnitedHealth Group, Inc., Strike Price USD 32, Expires 8/04/10, Broker Credit Suisse First Boston | 55,500 | (1,111) |
| Total Over-the-Counter Call Options Written | | (225,396) |
| Total Options Written (Premiums Received \$1,910,346) (0.8)% | | (1,601,136) |
| Total investments net of outstanding options written 102.2% | | 195,473,466 |
| Liabilities in Excess of Other Assets (2.2)% | | (4,174,739) |
| Net Assets 100.0% | | \$ 191,298,727 |

* The cost and unrealized appreciation (depreciation) of investments as of July 31, 2010, as computed for federal income tax purposes, were as follows:

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| | |
|-------------------------------|----------------|
| Aggregate cost | \$ 195,990,350 |
| Gross unrealized appreciation | \$ 8,838,389 |
| Gross unrealized depreciation | (7,754,137) |
| Net unrealized appreciation | \$ 1,084,252 |

- (a) Non-income producing security.
- (b) Security, or a portion thereof, pledged as collateral for outstanding options written.
- (c) Investments in companies considered to be an affiliate of the Trust, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

| Affiliate | Shares/ Beneficial Interest Held at October 31, 2009 | Net Activity | Shares/ Beneficial Interest Held at July 31, 2010 | Income |
|--|---|--------------|--|----------|
| BlackRock Liquidity Funds, TempFund, Institutional Class | 9,732,338 | 10,968,776 | 20,701,114 | \$ 7,658 |
| BlackRock Liquidity Series, LLC Money Market Series | 2,152,000 | (2,152,000) | | \$ 756 |

Schedule of Investments (concluded)**BlackRock Health Sciences Trust (BME)**
(Percentages shown are based on Net Assets)

(d) Represents current yield as of report date.

Foreign currency exchange contracts as of July 31, 2010 were as follows:

| | Currency Purchased | | Currency Sold | | Counterparty | Settlement Date | Unrealized Appreciation (Depreciation) |
|--------------|---------------------------|-----|----------------------|--|--------------------------|------------------------|---|
| USD | 735,769 | EUR | 562,000 | | UBS Securities LLC | 8/03/10 | \$ 3,399 |
| CHF | 483,000 | USD | 464,115 | | Deutsche Bank Securities | 8/04/10 | (430) |
| GBP | 100,000 | USD | 155,909 | | Deutsche Bank Securities | 8/04/10 | 1,002 |
| Total | | | | | | | <u>\$ 3,971</u> |

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or defined by Trust management. This definition may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivatives, which are as follows:

Level 1 price quotations in active markets/exchanges for identical assets and liabilities

Level 2 other observable inputs (including, but not limited to: quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available. In the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivatives)

The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and other significant accounting policies, please refer to the Trust's most recent financial statements as contained in its semi-annual report.

The following tables summarize the inputs used as of July 31, 2010 in determining the fair valuation of the Trust's investments and derivatives:

Valuation Inputs

| | Level 1 | Level 2 | Level 3 | Total |
|--|----------------|----------------|----------------|--------------|
|--|----------------|----------------|----------------|--------------|

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

| Assets: | | | |
|--|-----------------------|----------------------|-----------------------|
| Investments in Securities: | | | |
| Common Stocks: | | | |
| Biotechnology | \$ 22,885,686 | | \$ 22,885,686 |
| Chemicals | 1,088,340 | | 1,088,340 |
| Food Products | 313,596 | | 313,596 |
| Health Care Equipment & Supplies | 24,316,542 | \$ 1,212,310 | 25,528,852 |
| Health Care Providers & Services | 50,155,953 | 6,006,084 | 56,162,037 |
| Health Care Technology | 14,193,508 | | 14,193,508 |
| Life Sciences Tools & Services | 12,088,727 | 1,389,167 | 13,477,894 |
| Pharmaceuticals | 37,425,664 | 5,296,911 | 42,722,575 |
| Short-Term Securities | 20,701,114 | | 20,701,114 |
| Total | \$ 183,169,130 | \$ 13,904,472 | \$ 197,073,602 |

Derivative Financial Instruments¹

| Valuation Inputs | Level 1 | Level 2 | Level 3 | Total |
|--|-----------------------|---------------------|---------|-----------------------|
| Assets: | | | | |
| Equity contracts | \$ 1,000 | | | \$ 1,000 |
| Foreign currency exchange contracts | | \$ 4,401 | | 4,401 |
| Liabilities: | | | | |
| Equity contracts | (1,316,782) | (284,354) | | (1,601,136) |
| Foreign currency exchange contracts | | (430) | | (430) |
| Total | \$ (1,315,782) | \$ (280,383) | | \$ (1,596,165) |

¹ Derivative financial instruments are foreign currency exchange contracts and options. Foreign currency exchange contracts are shown at the unrealized appreciation/depreciation on the instrument and options are shown at value.

KEY TO ABBREVIATIONS

| | |
|-----|-----------------------------|
| ADR | American Depositary Receipt |
| CHF | Swiss Franc |
| EUR | Euro |
| GBP | British Pound |
| USD | U.S. Dollar |

JULY 31, 2010

4

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Item 2 Controls and Procedures

- 2(a) The registrant's principal executive and principal financial officers or persons performing similar functions have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act")) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.
- 2(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3 Exhibits

Certifications Attached hereto

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Health Sciences Trust

By: /s/ Anne F. Ackerley

Anne F. Ackerley
Chief Executive Officer of
BlackRock Health Sciences Trust

Date: September 27, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Anne F. Ackerley

Anne F. Ackerley
Chief Executive Officer (principal executive officer) of
BlackRock Health Sciences Trust

Date: September 27, 2010

By: /s/ Neal J. Andrews

Neal J. Andrews
Chief Financial Officer (principal financial officer) of
BlackRock Health Sciences Trust

Date: September 27, 2010
